These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38162902)

  • 1. Effects of dopaminergic treatment on inhibitory control differ across Hoehn and Yahr stages of Parkinson's disease.
    Mirabella G; Pilotto A; Rizzardi A; Montalti M; Olivola E; Zatti C; Di Caprio V; Ferrari E; Modugno N; Padovani A
    Brain Commun; 2024; 6(1):fcad350. PubMed ID: 38162902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-stage Parkinson's patients show selective impairment in reactive but not proactive inhibition.
    Di Caprio V; Modugno N; Mancini C; Olivola E; Mirabella G
    Mov Disord; 2020 Mar; 35(3):409-418. PubMed ID: 31755149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease.
    Ye Z; Altena E; Nombela C; Housden CR; Maxwell H; Rittman T; Huddleston C; Rae CL; Regenthal R; Sahakian BJ; Barker RA; Robbins TW; Rowe JB
    Brain; 2014 Apr; 137(Pt 4):1145-55. PubMed ID: 24578545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis.
    Schwarz J; Linke R; Kerner M; Mozley PD; Trenkwalder C; Gasser T; Tatsch K
    Arch Neurol; 2000 Feb; 57(2):205-8. PubMed ID: 10681078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects.
    Manza P; Amandola M; Tatineni V; Li CR; Leung HC
    NPJ Parkinsons Dis; 2017; 3():23. PubMed ID: 28702504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of disease severity and dopaminergic medication on recollection and familiarity in patients with idiopathic nondementing Parkinson's.
    Edelstyn NM; Shepherd TA; Mayes AR; Sherman SM; Ellis SJ
    Neuropsychologia; 2010 Apr; 48(5):1367-75. PubMed ID: 20036678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Iowa Gambling Task in Parkinson's disease: A meta-analysis on effects of disease and medication.
    Evens R; Hoefler M; Biber K; Lueken U
    Neuropsychologia; 2016 Oct; 91():163-172. PubMed ID: 27475264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease.
    Wylie SA; van Wouwe NC; Godfrey SG; Bissett PG; Logan GD; Kanoff KE; Claassen DO; Neimat JS; van den Wildenberg WPM
    Neuropsychologia; 2018 Jan; 109():262-269. PubMed ID: 29269306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and relative factors of constipation in a cohort of Chinese patients with Parkinson's disease.
    Sun BH; Wang T; Li NY; Wu Q; Qiao J
    World J Gastrointest Pharmacol Ther; 2021 Jan; 12(1):21-31. PubMed ID: 33564494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease.
    Jahanshahi M; Jones CR; Zijlmans J; Katzenschlager R; Lee L; Quinn N; Frith CD; Lees AJ
    Brain; 2010 Mar; 133(Pt 3):727-45. PubMed ID: 20305278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition.
    Rowe JB; Hughes L; Ghosh BC; Eckstein D; Williams-Gray CH; Fallon S; Barker RA; Owen AM
    Brain; 2008 Aug; 131(Pt 8):2094-105. PubMed ID: 18577547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson's disease patients OFF and ON medications.
    Kim J; Zhang K; Cai W; YorkWilliams S; Ua Cruadhlaoich MAI; Llanes S; Menon V; Poston KL
    Neuropsychologia; 2018 Oct; 119():24-33. PubMed ID: 30040957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease stage dependency of motor and non-motor fluctuations in Parkinson's disease.
    Storch A; Rosqvist K; Ebersbach G; ; Odin P
    J Neural Transm (Vienna); 2019 Jul; 126(7):841-851. PubMed ID: 31218469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and clinical correlates of retrocollis in Parkinson's disease.
    Kashihara K; Imamura T
    J Neurol Sci; 2013 Jan; 324(1-2):106-8. PubMed ID: 23151424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discussing sexual health among Flemish patients with Parkinson's disease.
    Van Overmeire R; Vesentini L; Vanclooster S; Bilsen J
    Acta Neurol Belg; 2023 Apr; 123(2):497-505. PubMed ID: 36153464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the dopamine overdose hypothesis in action control: A study in people with Parkinson's disease.
    Ruitenberg MFL; Abrahamse EL; Santens P; Notebaert W
    J Neuropsychol; 2023 Jun; 17(2):264-278. PubMed ID: 36303524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson's Disease.
    Rosqvist K; Odin P; Hagell P; Iwarsson S; Nilsson MH; Storch A
    J Parkinsons Dis; 2018; 8(3):409-420. PubMed ID: 30056433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-emergent tremor in Parkinson's disease: the effect of dopaminergic treatment.
    Belvisi D; Conte A; Cutrona C; Costanzo M; Ferrazzano G; Fabbrini G; Berardelli A
    Eur J Neurol; 2018 Jun; 25(6):799-804. PubMed ID: 29512863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age at Parkinson's disease onset modulates the effect of levodopa on response inhibition: Support for the dopamine overdose hypothesis from the antisaccade task.
    Waldthaler J; Stock L; Krüger-Zechlin C; Timmermann L
    Neuropsychologia; 2021 Dec; 163():108082. PubMed ID: 34728241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.